ARASTEP trial evaluates darolutamide plus ADT for high-risk biochemical recurrence of prostate cancer, focusing on radiologic progression-free survival (rPFS) by PSMA PET-CT. The study involves 970 ...

Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone ...

Padeliporfin VTP therapy shows high efficacy with an 86.5% overall response rate and 73% complete response rate in low-grade UTUC. The therapy provides an organ-sparing alternative to ...

Panelist discusses how urologists can benefit from adopting newer treatment modalities like aqua ablation for BPH, emphasizing its growing popularity, ease of learning, and efficiency in improving ...

Exploring the impact of ultra-sensitive PSA testing on treatment decisions for metastatic hormone-sensitive prostate cancer, enhancing patient outcomes and care efficiency. Dr Shore provided guidance ...

UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...

Cytoreductive nephrectomy (CN) remains vital in mRCC management, with immune checkpoint inhibitors (ICI) reshaping treatment strategies and patient selection criteria. The SCREEN score offers superior ...

CT scans remain the most common initial imaging modality for renal mass detection. MRI offers additional sequencing capabilities for better tumor characterization. Ultrasound primarily helps determine ...

The relationship between clinical trial results and real-world experience with enzalutamide and darolutamide shows important patterns: The alignment between trial data and clinical experience supports ...

A panelist discusses how they would communicate these comparative study results to patients by explaining that both enzalutamide and darolutamide effectively control metastatic prostate cancer when ...

Investigators found that benefits of treatments that are observed in trials also appear in the real world. A recent study examined the relationship between randomized controlled trials and real-world ...

Paul E. Dato, MD, discusses how a 69-year-old Black man presented with metastatic hormone-sensitive prostate cancer, showing symptoms of fatigue, nocturia, back pain, and weight loss, with initial ...